Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

TRIADIC CROSSTALK IN CUTANEOUS AGING MOLECULAR MECHANISMS AND THERAPEUTIC OPPORTUNITIES

Ms. Mitali Singh[1], Mrs. Shruti Varshney[2], Ms. Pooja Chaurasia[3], Dr. Charu Khanna[4], Dr. Prashant Mathur[5], Dr. Pragya Prashant Gupta[6], Dr. Ashish Kumar[7], Mr. Panshul Chauhan[8],*Ms. Rachana Belwal[9]

[1]Assistant Professor, Sahu Onkar Saran School of Pharmacy, IFTM University, Lodipur-Rajput, Delhi Road, NH-24, Moradabad, Uttar Pradesh, India, Pin Code-244102
[2]Associate Professor, Noida Institute of Engineering and Technology(Pharmacy Institute), Greater Noida, Uttar Pradesh, India, Pin Code- 201306
[3]Assistant Professor, IIMT College of Pharmacy, Greater Noida, Gautam Budh Nagar, Uttar Pradesh, India, Pin Code- 201306
[4]Professor and Dean, Mind Power University, Bhimtal, Bohrakoon, Nainital, Uttarakhand, India, Pin Code- 263136
[5]Principal, MJRP College of Pharmacy, MJRP University, Jaipur, Rajasthan, India, Pin Code- 303909
[6]Professor and Dean, Faculty of Management and Commerce, Future University, Bareilly,Uttar Pradesh, India, Pin Code- 243503
[7]Associate Professor, Faculty of Pharmaceutical Sciences, Future University, Bareilly, Uttar Pradesh, India, Pin Code-243503
[8]Assistant Professor, Integrated Academy of Management and Technology, Dasna, Ghaziabad, Uttar Pradesh, India, Pin Code- 201013
[9]Assistant Professor, Department of Pharmaceutical Chemistry, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Dehradun, Uttarakhand, India, Pin Code -248007

*Corresponding Author
Ms. Rachana Belwal

Article History
Received: 17.09.2025
Revised: 09.10.2025
Accepted: 29.10.2025
Published: 12.11.2025

Abstract: Skin aging represents a complex biological phenomenon orchestrated by the interplay of intrinsic genetic programs and extrinsic environmental factors. Recent advances have illuminated three pivotal molecular axes—cellular senescence, epigenetic reprogramming, and the cutaneo-microbial ecosystem—as interdependent drivers of age-associated cutaneous decline. Senescent cells, characterized by stable proliferative arrest and a proinflammatory secretory phenotype, accumulate with age and contribute to dermal atrophy and impaired regeneration. Concurrently, age-related epigenetic drift, encompassing aberrant DNA methylation patterns, histone modifications, and non-coding RNA activity, reshapes the chromatin landscape and modulates gene expression critical for skin integrity. In parallel, the skin microbiome undergoes compositional and functional shifts that exacerbate inflammaging and barrier dysfunction. This review synthesizes emerging evidence at the convergence of these domains, highlighting mechanistic crosstalk and bidirectional regulation. We further explore therapeutic strategies that target this triad, including senolytics, epigenetic modifiers, and microbiome-based interventions, emphasizing their translational potential and challenges in clinical implementation. By adopting an integrative lens, we propose a systems-biology framework to advance precision dermatology in the context of aging.

Keywords: Skin Aging; Cellular Senescence; Epigenetic reprogramming; Cutaneous microbiome and Senotherapeutics.

INTRODUCTION

Skin aging is a multifactorial and dynamic process characterized by progressive functional decline, structural deterioration, and increased susceptibility to environmental insults. Traditionally categorized into intrinsic (chronological) and extrinsic (photoaging) components, cutaneous aging is now increasingly understood as a systems-level phenomenon governed by intricate molecular and cellular networks [1]. Central among these are three interrelated biological axes: cellular senescence, epigenetic dysregulation, and the skin microbiome. Each contributes uniquely to the aging phenotype, yet emerging evidence reveals significant crosstalk and convergence among these mechanisms, suggesting the need for an integrative analytical framework [2,3]. Cellular senescence, marked by irreversible cell cycle arrest and a proinflammatory secretory profile, acts as both a driver and hallmark of skin aging. Concurrently, age-associated epigenetic remodeling—including altered DNA methylation, histone code perturbations, and deregulation of non-coding RNAs—reshapes gene expression landscapes vital for epidermal and dermal homeostasis. Simultaneously, age-related shifts in the skin microbiota—characterized by reduced diversity, pathogen enrichment, and disruption of symbiotic interactions—have been implicated in impairing barrier function and promoting chronic low-grade inflammation, or "inflammaging."This review aims to elucidate the molecular interplay among senescence, epigenetics, and the cutaneous microbiome within the context of skin aging [4]. By synthesizing mechanistic insights and highlighting emerging intersections, we propose a conceptual model that captures their bidirectional influences and translational relevance [5,6]. Furthermore, we explore how these converging pathways offer therapeutic opportunities, paving the way for novel interventions that are not only effective but also personalized and systemically attuned [7].

1.1 Search Methodology

A comprehensive and structured literature search was conducted to synthesize current insights into the molecular mechanisms and therapeutic strategies associated with skin aging. Electronic databases including PubMed, Scopus, Web of Science, and Google Scholar were searched for peer-reviewed articles published between January 2005 and May 2025, with a strong emphasis on literature from the last five to

seven years to ensure relevance and recency. The search strategy incorporated a combination of controlled vocabulary and free-text keywords, including: "skin aging," "cellular senescence," "SASP (senescence-associated secretory phenotype)," "epigenetic drift," "DNA methylation," "histone modifications," "non-coding RNAs," "cutaneous microbiome," "microbial dysbiosis," "senotherapeutics," "epigenetic reprogramming," and "microbiome-based therapy." Special focus was given to studies that explored mechanistic crosstalk, multi-omics analyses, or novel therapeutic modalities that bridged at least two of the triadic axes: senescence, epigenetics, and microbiome imbalance. Manual curation of reference lists from key reviews and experimental papers was also performed to identify seminal or cross-disciplinary contributions not retrieved in the primary search. Articles were screened based on relevance, experimental depth, and translational applicability, with exclusion criteria applied to non-English language publications, non-peer-reviewed materials, and studies lacking mechanistic detail. This search methodology enabled the construction of a triadic systems biology narrative that reflects the evolving landscape of precision dermatology in the context of aging.

2. Cellular Senescence and Skin Aging

Cellular senescence constitutes a fundamental biological process underlying cutaneous aging, manifesting as a stable growth arrest in response to cumulative stress signals such as telomere attrition, genotoxic insults, mitochondrial dysfunction, and oncogene activation. In the context of the skin, this senescent arrest occurs predominantly in dermal fibroblasts, basal keratinocytes, melanocytes, and even skin-resident immune cells—each contributing distinctively to the aging phenotype [8,9].

Morphologically, senescent cells display enlarged, flattened architecture with increased β-galactosidase activity at pH 6.0 (SA-β-Gal), alongside persistent DNA damage foci marked by γH2AX and 53BP1 [10,11]. Transcriptionally, they upregulate key cell cycle inhibitors, particularly p16^INK4a, p21^CIP1, and p53, initiating an irreversible blockade of mitotic progression. However, senescence is not merely a cell-autonomous fate—it is a dynamic tissue-altering phenomenon [12].

Central to its pathological impact is the senescence-associated secretory phenotype (SASP), a cocktail of proinflammatory cytokines (IL-6, IL-8), chemokines (MCP-1, CXCL1), matrix-degrading enzymes (MMP-1, MMP-3), and growth modulators (VEGF, TGF-β). SASP factors alter the extracellular matrix (ECM), promote melanogenesis, impair basement membrane integrity, and propagate a proinflammatory microenvironment that sustains paracrine senescence and immune dysregulation [13]. In skin, the dermal-epidermal junction becomes fragmented, collagen networks disorganized, and epidermal renewal capacity diminished [14,15].

Recent high-dimensional profiling, including single-cell RNA sequencing and spatial transcriptomics, has revealed heterogeneity in senescent cell subtypes and temporal niches. Not all senescent cells are equal: certain populations appear transient and reparative (e.g., during wound healing), while others persist and become deleterious with age [16]. Moreover, cross-talk between senescent fibroblasts and immune surveillance networks—particularly macrophages and T cells—is vital for either their clearance or chronic retention [17,18,19].

From a therapeutic perspective, interventions are rapidly evolving from broad-spectrum cytotoxins to finely tuned senolytics (e.g., dasatinib + quercetin, navitoclax) and senomorphics (e.g., JAK inhibitors, metformin) with topical applicability. However, efficacy hinges on the precision of delivery and the ability to distinguish detrimental senescence from transient physiological roles [20]. A nuanced understanding of senescence trajectory, including epigenomic and metabolic reprogramming within aged skin, is critical to optimizing therapeutic outcomes [21].

3. Epigenetic Modifications in Skin Aging

The aging process at the cutaneous level is orchestrated not solely by genomic damage but by nuanced, heritable yet reversible epigenetic modifications that dictate transcriptional plasticity. In aged skin, the fidelity of epigenetic programming gradually erodes, leading to aberrant gene expression patterns that impair cellular differentiation, proliferation, and tissue regeneration. These epigenetic alterations include DNA methylation drift, histone mark remodeling, and non-coding RNA-mediated regulatory shifts—all of which contribute to the progressive loss of skin homeostasis [22].

3.1. DNA Methylation Landscape and Epigenetic Drift

Skin aging is accompanied by a global hypomethylation of CpG dinucleotides, interspersed with region-specific hypermethylation of promoter-associated CpG islands [23]. These alterations compromise genomic stability and transcriptional regulation of genes involved in ECM remodeling, barrier function, and stem cell maintenance [24]. Notably, tissue-specific epigenetic clocks—such as skin & blood DNA methylation clocks—have emerged as robust biomarkers correlating methylation patterns with biological skin age, outperforming chronological indices. Hypermethylation of key homeobox genes and transcriptional regulators in dermal fibroblasts, for example, contributes to the loss of positional identity and dermal atrophy [25].

3.2. Histone Code Reprogramming and Chromatin Architecture

Aging skin exhibits profound modifications in the histone landscape, particularly involving reduced levels of histone acetylation (e.g., H3K9ac) and trimethylation (e.g., H3K27me3) at loci controlling genes implicated in cell cycle regulation and mitochondrial function. These shifts are associated with increased chromatin compaction or decompaction at lineage-defining loci, resulting in transcriptomic noise and diminished cellular plasticity [26,27]. Furthermore, the expression of histone-modifying enzymes such as HDACs, EZH2, and SIRT1 is dysregulated with age, disrupting enhancer–promoter communication and impairing the regenerative capacity of epidermal progenitors [28].

3.3. Role of non-coding RNAs in Cutaneous Epigenetic Regulation

A diverse repertoire of long non-coding RNAs (lncRNAs) and microRNAs (miRNAs) orchestrate epigenetic regulation in skin aging by modulating the expression of chromatin remodelers and key transcription factors. For instance, miR-29 and miR-34 families are upregulated in aged skin and target collagen-encoding genes and anti-apoptotic regulators, respectively, potentiating tissue degradation and senescence. Conversely, downregulation of regenerative miRNAs (e.g., miR-200 family) contributes to impaired keratinocyte differentiation and delayed wound closure. lncRNAs such as HOTAIR and ANCR have also been implicated in modulating histone methylation complexes and epidermal stem cell quiescence, respectively [29].

3.4. Epigenetic Crosstalk with Microenvironmental Cues

Epigenetic alterations in skin cells are not isolated but respond dynamically to external stressors such as UV radiation, pollution, and microbiota-derived metabolites. UV-induced thymine dimers and oxidative stress activate damage-responsive transcriptional programs through alterations in the epigenome, including accelerated methylation drift and histone modification turnover [30]. Emerging data also suggest that microbial metabolites like butyrate and short-chain fatty acids can modulate HDAC activity in keratinocytes and influence gene regulatory networks associated with barrier repair and inflammation [31].

4. The Skin Microbiome in Aging

The cutaneous microbiome—comprising bacteria, fungi, viruses, and archaea exists in a dynamic, symbiotic relationship with its human host, playing a critical role in maintaining skin homeostasis, immune regulation, and barrier integrity. With advancing age, this microbial ecosystem undergoes substantial compositional, functional, and spatial reconfiguration that contributes to phenotypic features of skin aging and enhances susceptibility to dermatological disorders [32].

4.1. Age-Driven Dysbiosis and Microbial Succession

Aging is associated with both quantitative and qualitative alterations in skin microbiota, commonly referred to as microbial dysbiosis. Longitudinal analyses reveal a decline in microbial diversity and an increased inter-individual variability among elderly populations. Specifically, beneficial commensals such as *Cutibacterium acnes* (formerly *Propionibacterium acnes*), *Staphylococcus epidermidis*, and certain Corynebacterium species often decline, while opportunistic pathogens like *Staphylococcus aureus* and *Malassezia globosa* expand in niche dominance. These transitions may reflect cumulative extrinsic exposures (e.g., UV, cosmetics, hygiene), intrinsic immunosenescence, and sebaceous gland atrophy [33,34].

4.2. Functional Shifts and Metabolic Rewiring

Beyond taxonomy, the metabolic output and functional potential of the aging skin microbiome are markedly altered. Metagenomic and metabolomic studies suggest reduced biosynthetic capabilities for key antimicrobial peptides (AMPs), ceramide processing enzymes, and short-chain fatty acids—all of which are critical for sustaining the skin's acid mantle and antimicrobial barrier. Additionally, microbial-mediated tryptophan metabolism and vitamin B production decline with age, impairing epithelial nutrient availability and increasing oxidative susceptibility [35].

Age-associated changes in microbial quorum sensing and biofilm formation further disrupt host-microbe symbiosis. For example, dysbiotic strains may exhibit enhanced virulence, altered lipase activity, or immunoevasive properties, thereby subverting epidermal immunity and facilitating chronic low-grade inflammation [36,37].

4.3. Microbiota–Immune Crosstalk and Inflammaging

The skin's immune landscape—particularly Langerhans cells, tissue-resident memory T cells, and keratinocyte cytokine networks—is intricately shaped by microbial cues. In aged skin, impaired microbial recognition (e.g., via TLR2, NOD2 signaling), reduced AMP production, and altered antigen presentation compromise immune surveillance and lead to a proinflammatory milieu. This breakdown in immune-microbial homeostasis contributes to inflammaging, an age-related phenomenon characterized by persistent low-grade inflammation. Microbial metabolites can engage aryl hydrocarbon receptors (AhR) and histamine receptors, modulating barrier gene expression, keratinocyte proliferation, and stress responses. Imbalances in these signaling networks disrupt tissue repair and accelerate dermal thinning [38].

4.4. Ecological Interactions and Topographical Remodeling

The aging process remodels the skin’s topography—reduced hydration, altered sebum composition, and

wrinkling—each of which reshapes microbial habitat availability. For instance, sebaceous sites become drier and less hospitable to lipophilic commensals like *C. acnes*, while eccrine-rich regions may exhibit shifts in osmotic pressure and pH, influencing bacterial competitiveness [39].

Moreover, the microbiome exhibits biogeographical drift with aging: the relative abundance of microbial taxa changes not only by site (e.g., forehead vs. forearm) but also by depth, affecting the follicular niche versus the stratum corneum. This vertical and lateral stratification may have functional implications for microbial metabolite diffusion and host signaling [40].

4.5. Therapeutic Targeting of the Aging Microbiome

Emerging strategies aim to restore microbial homeostasis in aging skin. These include topical probiotics, prebiotics, postbiotics, and microbiome-friendly formulations that enhance beneficial taxa while suppressing pathobionts. Advances in synthetic biology and phage therapy offer targeted microbial editing without invoking broad-spectrum antimicrobial resistance. Importantly, microbiome-targeted therapies must consider host age, immune status, and skin biophysical parameters for efficacy. Integration with senescence modulation and epigenetic interventions may yield synergistic benefits, given the bidirectional crosstalk among these axes [41].

5. Crosstalk at the Molecular Interface: Interconnected Pathways in Skin Aging

The aging phenotype in skin is not the product of isolated molecular events but the result of intricate, multidirectional signaling circuits between senescent cells, the host epigenome, and resident microbiota. This convergence engenders a self-reinforcing loop of dysregulation that amplifies tissue degradation, immunologic perturbation, and metabolic dysfunction over time.

5.1. Senescence-Induced Epigenomic Reprogramming

Cellular senescence is not solely governed by epigenetic changes—it is also a potent driver of them. Upon transition into the senescent state, cells undergo profound chromatin remodeling, including the formation of senescence-associated heterochromatin foci (SAHF), which silence proliferation-promoting genes. These changes involve redistribution of heterochromatic histone marks (e.g., H3K9me3, H4K20me3) and are mediated by altered expression of chromatin remodelers like HMGA1 and SUV39H1 [42].

Moreover, senescent fibroblasts and keratinocytes exhibit large-scale DNA hypomethylation and site-specific promoter hypermethylation, reshaping gene regulatory networks beyond the senescent cell itself. These alterations contribute to long-range changes in the transcriptomic landscape of the tissue microenvironment, affecting stem cell niches and repair capacity. Importantly, SASP-derived cytokines such as IL-6 and IL-8 can induce epigenetic drift in neighboring non-senescent cells via JAK-STAT and NF-κB activation, suggesting that epigenetic aging can propagate in a non–cell-autonomous manner [43].

5.2. Microbiome–Epigenome Interactions: Metabolic and Epigenetic Interfacing

Microbial communities residing on the skin surface secrete a wide array of bioactive metabolites—such as short-chain fatty acids (SCFAs), folate derivatives, polyamines, and histone deacetylase (HDAC) inhibitors—that can penetrate epidermal layers and directly modulate host epigenetic machinery. For instance, acetate and butyrate produced by commensals inhibit HDACs, altering histone acetylation and promoting transcription of genes involved in barrier maintenance and immunomodulation [44,45].

Conversely, epigenetic changes in host keratinocytes can influence microbial colonization patterns by modifying lipid secretion profiles, antimicrobial peptide expression (e.g., cathelicidins, defensins), and receptor availability for microbial adhesion. This bidirectional modulation establishes a host-epigenetic–microbial feedback loop, wherein disturbances in microbial diversity or metabolite availability can accelerate epigenetic aging trajectories and vice versa [46].

5.3. Senescence–Microbiome Crosstalk: A Proinflammatory Nexus

Senescent skin cells reshape microbial habitats both structurally and biochemically. SASP factors alter the local pH, osmolarity, and lipid landscape, favoring the colonization of pathobionts such as *Staphylococcus aureus* while diminishing niches for mutualistic commensals. In parallel, microbial dysbiosis exacerbates local inflammation and oxidative stress, reinforcing paracrine senescence via activation of pattern recognition receptors (e.g., TLR2, NOD1/2) and downstream inflammasomes (NLRP3) [47].

Of particular interest is the role of microbial pathogen-associated molecular patterns (PAMPs) in modulating senescent phenotypes. Chronic exposure to microbial ligands—especially in compromised barrier conditions—triggers aberrant NF-κB and MAPK signaling, upregulating SASP expression and skewing local immune responses toward a persistent, low-grade proinflammatory state [48].

5.4. Convergence Points: Molecular Hubs Linking the Triad

Recent systems biology analyses have begun to identify key molecular integrators—such as AhR, SIRT1, mTOR, and DNA methyltransferases (DNMTs)—as convergence points for signals emanating from senescence, microbial cues, and epigenetic states. For example, AhR activation by microbial metabolites or environmental toxins modulates gene expression in

epidermal cells and also influences senescence and oxidative stress responses [49].

Moreover, SIRT1 serves as a redox-sensitive regulator that modulates both histone deacetylation and inflammation, bridging metabolic status, chromatin architecture, and cellular lifespan. These nodes represent promising targets for multi-axis therapeutic intervention, enabling synchronized modulation of the aging skin ecosystem[50,51].

5.5 Evidence Synthesis: Triadic Mechanisms in Aging Skin

Recent studies across cellular, molecular, and microbial disciplines reveal that skin aging is not a unidimensional process but the result of interlinked dysfunctions in senescence biology, epigenetic regulation, and microbial ecology [52]. Senescence-associated decline begins with the accumulation of metabolically active but non-proliferative fibroblasts and keratinocytes in aged skin. These cells secrete a cocktail of pro-inflammatory cytokines and proteases, collectively referred to as the senescence-associated secretory phenotype (SASP), including IL-6, IL-8, GM-CSF, and MMPs. Researcher [53] provided compelling evidence that aged human dermis displays elevated levels of MMP-1 and MMP-3, directly correlating with collagen fragmentation and loss of tensile strength. Functional rejuvenation studies, such as those by researcher [54], have further validated the deleterious role of these cells—demonstrating that pharmacologic senolysis using ABT263 reverses skin thinning and restores dermal matrix composition in aged mice.

Concurrently, aging is marked by profound alterations in the skin's epigenetic landscape. These include global DNA hypomethylation—resulting in genome instability—and region-specific promoter hypermethylation of genes critical for proliferation and differentiation. Researcher analyzed methylomes of young and aged human epidermis and revealed aberrant methylation patterns in loci regulating keratinocyte dynamics and extracellular matrix integrity. Moreover, researcher reported age-associated downregulation of key chromatin-modifying enzymes such as DNMT1 and SIRT1 in keratinocytes, resulting in chromatin relaxation and transcriptional noise—conditions conducive to inflammaging and impaired regeneration.
The skin microbiome also undergoes significant shifts with age, both in community composition and functional output. Using 16S rRNA sequencing, researcher [55] showed a depletion of *Cutibacterium acnes* and enrichment of *Staphylococcus aureus* and *Corynebacterium spp*. on aged skin. These taxa are associated with elevated expression of microbial genes involved in inflammation, biofilm formation, and antibiotic resistance.

Emerging cross-disciplinary studies now illustrate that these three aging axes are mechanistically interconnected. For instance, researcher discovered that extracellular vesicles from senescent fibroblasts contain regulatory microRNAs capable of inducing chromatin remodeling in recipient keratinocytes—thus linking senescence and epigenetic drift. Similarly, researcher reported that bacterial metabolites such as short-chain fatty acids (SCFAs) influence histone acetylation patterns in skin-resident immune cells, modulating their differentiation and AMP expression.

Together, this evidence converges on a triadic aging model in which cellular senescence, epigenetic dysregulation, and microbial imbalance sustain one another in a feedback loop, accelerating the decline of skin structure, function, and regenerative capacity. This integrated understanding supports the rationale for multimodal therapeutic strategies that can interrupt crosstalk among these axes and restore cutaneous homeostasis [56,57].

6. Therapeutic Interventions: Targeting the Triad

The convergence of cellular senescence, epigenetic dysregulation, and microbial imbalance in skin aging presents a unique opportunity for multifocal therapeutic intervention. Rather than addressing these processes in isolation, emerging strategies seek to modulate their molecular interfaces, aiming to restore homeostasis, attenuate inflammation, and reprogram cellular and ecological memory [58].

6.1. Senotherapeutics: Eliminating and Reprogramming Senescent Cells

Senotherapeutic modalities encompass both senolytics—which selectively eliminate senescent cells—and senomorphics, which suppress SASP without inducing apoptosis. In dermatological contexts, agents like navitoclax (a BCL-2/BCL-XL inhibitor) and natural polyphenols such as fisetin or quercetin have demonstrated efficacy in preclinical skin models, reducing dermal senescent burden and improving ECM integrity. Topical delivery systems employing liposomes, microneedles, or nanocarriers have shown promise in overcoming barrier limitations and targeting senescent fibroblasts in situ [59].

Moreover, transient reprogramming strategies using Yamanaka factors or mRNA constructs are under investigation to reverse senescent phenotypes without full dedifferentiation. These approaches are postulated to epigenetically rejuvenate skin cells by resetting chromatin states, potentially reactivating regenerative transcriptional programs [60].

6.2. Epigenetic Modulators: Rewriting the Aging Transcriptome

Intervening at the level of the epigenome requires precise modulation of histone marks, methylation status, and non-coding RNA activity. HDAC inhibitors (e.g., trichostatin A, entinostat) and DNMT inhibitors (e.g., 5-azacytidine) are being repurposed at

subtherapeutic concentrations for topical or localized cutaneous use to restore chromatin accessibility and stem cell function. Additionally, SIRT1 activators such as resveratrol derivatives aim to restore NAD+-dependent deacetylation, a hallmark of youthful chromatin architecture [61].

RNA-based therapeutics, including antagomiRs and lncRNA mimics, offer sequence-specific regulation of aging-associated transcripts, although challenges in stability and cutaneous delivery remain. Integrating these tools with transcriptomic mapping can enable the personalized correction of age-altered epigenetic signatures [62].

6.3. Microbiome-Targeted Therapies: Restoring Ecological Equilibrium

Therapeutic strategies targeting the aging skin microbiome aim not just to replenish beneficial species but to modulate microbial metabolites and host–microbe signaling axes. Topical probiotics containing *Staphylococcus epidermidis* or *Lactobacillus reuteri* have demonstrated anti-inflammatory and barrier-enhancing effects. Prebiotics, such as inulin or xylitol derivatives, selectively enrich resident symbionts and enhance AMP production. An emerging class of interventions—postbiotics—utilizes microbial-derived metabolites (e.g., SCFAs, indoles, bacteriocins) to modulate keratinocyte function and immune tone without introducing live organisms. Meanwhile, bacteriophage therapy and CRISPR-based microbial editing offer precision in depleting pathogenic taxa without disrupting broader microbial diversity as shown in Figure 1. [63].

6.4. Integrative Approaches: Synergistic and Personalized Modalities

Given the interdependence of senescence, epigenetics, and the microbiome, combinatorial strategies are gaining traction. Co-delivery of senolytics and HDAC inhibitors, for instance, may enhance clearance of deleterious cell populations while reactivating regenerative genes. Simultaneously, modulating the microbiome may amplify epigenetic remodeling by altering the local metabolome, enabling a microenvironment conducive to repair. Personalized regimens guided by multi-omics profiling—integrating methylation clocks, SASP signatures, and microbiome composition—will be essential for stratifying patients and predicting therapeutic responsiveness. Such stratification may facilitate the development of precision dermatogeriatrics, a field that tailors interventions to biological rather than chronological skin age.A consolidated overview of emerging therapeutic strategies across the three interlinked aging axes—cellular senescence, epigenetic dysregulation, and microbiome imbalance—is presented in Table X. This table summarizes the biological targets, mechanistic rationale, representative agents, delivery platforms, and translational status, offering a roadmap for precision-based anti-aging interventions [64,65].

RESULTS AND OBSERVATIONS:

Graphical Abstract





Figure 1: Targeting the Interconnected Molecular Drivers of Skin Aging: A Systematic- Based Therapeutics Framework

Table 1. Comprehensive Overview of Therapeutic Strategies Targeting the Triadic Hallmarks of Skin Aging

Aging Axis	Biological Target	Mechanistic Rationale	Therapeutic Strategy	Representative Agents / Interventions	Delivery Platforms	Translational Status
Cellular Senescence	Senescent fibroblasts, keratinocytes	Eliminate or modulate SASP-producing cells to reduce ECM degradation and inflammation	Senolytics	Dasatinib + Quercetin, Navitoclax, ABT263, Fisetin	Liposomes, microneedles, solid lipid nanoparticles	Preclinical to Phase I
	SASP signaling (IL-6, IL-8, MMPs)	Suppress inflammatory milieu and tissue remodeling	Senomorphics	JAK inhibitors (e.g., Ruxolitinib), Metformin, Rapamycin	Hydrogels, topical creams	Investigational
	Senescence reprogramming	Rejuvenate aged cells without full dedifferentiation	Transient reprogramming	mRNA Yamanaka factors, OSK factors	Nanocarriers, exosome mimetics	Experimental
Epigenetic Dysregulation	Global DNA hypomethylation / promoter hypermethylation	Restore chromatin accessibility and youthful gene expression	DNMT / HDAC inhibitors	5-Azacytidine, RG108, Trichostatin A, Vorinostat	Polymeric nanoparticles, microemulsions	Early-stage
	Sirtuin pathway modulation	Enhance chromatin stability and oxidative resilience	SIRT1 activators	Resveratrol, SRT2104, NAD+ boosters	Oral, topical nano-gels	Phase I–II
	miRNA / lncRNA imbalance	Correct non-coding RNA signatures	RNA therapeutics	miR-34a inhibitors, ANCR	RNA-lipid complexes, dermal	Experimental

		regulating aging		mimics, lncRNA oligonucleotides	patches	
Microbiome Imbalance	Dysbiosis of commensals vs. pathogens	Restore microbial homeostasis, AMP production, immune balance	Topical probiotics	S. epidermidis, L. reuteri	Probiotic creams, live gel patches	Clinical trials (eczema, aging skin)
	Loss of microbial metabolites (SCFAs, vitamins)	Modulate host-microbe signaling and inflammation	Postbiotics / Metabolite therapy	Butyrate, indoles, bacteriocins, tryptophan derivatives	Hydrogel dressings, smart-release creams	In development
	Overgrowth of pathobionts	Selective removal of harmful species	Bacteriophage / CRISPR microbiome editing	Phage lysins, CRISPR-guided editing tools	Precision microbe gels	Experimental
Triadic Crosstalk	AhR, SIRT1, mTOR, NF-κB hubs	Simultaneously target senescence, epigenome, and microbiota for synergy	Multi-axis combination therapy	Dual HDACi + Senolytic; Resveratrol + Probiotics	Co-encapsulated nanogels, responsive microneedle arrays	Next-gen strategy, under exploration
	Diagnostic biomarkers (SASP, methylation, microbiome)	Personalize therapy based on biological aging profile	Multi-omics–guided personalization	Methylation clocks, microbiome panels, SASP arrays	Skin swabs + AI skin scanners	Rapidly emerging

DISCUSSION

7. Translational Perspectives and Delivery Challenges

Despite compelling molecular insights into senescence, epigenetic reprogramming, and the skin microbiome, translating these discoveries into effective, clinically viable therapies remains fraught with complexity. The intrinsic heterogeneity of skin architecture, coupled with its dynamic exposure to environmental stressors, presents formidable barriers to bioactive delivery, pharmacokinetic optimization, and personalized intervention [66].

7.1. Cutaneous Pharmacokinetics and Barrier Limitations

The stratum corneum, while essential for host defense, acts as a formidable obstacle for transdermal delivery of large, charged, or hydrophilic molecules—properties typical of many senotherapeutics, epigenetic agents, and microbiome modulators [67,68]. Moreover, age-induced alterations in lipid composition, hydration, and surface pH further modulate drug penetration kinetics and may necessitate age-specific delivery strategies [69].

Advances in nanocarrier engineering—including lipid-based vesicles (liposomes, ethosomes), polymeric nanoparticles, dendrimers, and solid lipid nanoparticles—have shown promise in enhancing percutaneous absorption, cargo protection, and site-specific targeting. For instance, encapsulating senolytics in amphiphilic polymer systems facilitates fibroblast-specific uptake, while preserving systemic safety [70].

7.2. Microneedles, Hydrogels, and Responsive Platforms

Microneedle arrays, particularly dissolvable and hydrogel-forming types, are garnering attention for minimally invasive, sustained delivery of high molecular weight therapeutics. When integrated with stimuli-responsive systems—triggered by pH, ROS, or enzymatic activity—microneedles can enable localized, on-demand release of SASP inhibitors or HDAC modulators in aged dermis. Hydrogel platforms further offer an adaptable scaffold for co-delivery of therapeutic cocktails, including living probiotics or postbiotic peptides. Functionalization with cell-adhesion motifs and ECM-mimetic components enhances bio integration, especially critical for restoring dermal architecture in aged or photoaged skin [71].

7.3. Formulation Stability and Biocompatibility

Epigenetic drugs and live microbial products present significant formulation hurdles. Many small molecule modulators (e.g., DNMT inhibitors) are chemically

unstable or light-sensitive, necessitating advanced encapsulation and stabilization techniques. Live biotherapeutic products, such as engineered commensals, require tight cold-chain management, low-shear dispersal methods, and compatibility with skin microbiota to avoid dysbiosis [72].

Ensuring biocompatibility and immunotolerance is paramount, particularly in aged individuals with heightened susceptibility to contact dermatitis, immune senescence, and delayed wound repair. The immunogenicity profile of novel carriers and excipients must therefore be rigorously evaluated, ideally using age-matched ex vivo human skin or organotypic 3D models [73].

7.4. Patient Stratification and Omics-Guided Personalization

Inter-individual variability in aging trajectories necessitates biomarker-driven therapeutic design. High-throughput epigenomic, transcriptomic, and microbiomic profiling enables classification of patients into distinct aging subtypes, such as "inflammaging-dominant," "epigenetically drifted," or "microbial-depleted" phenotypes. Stratified interventions can thereby be matched to the dominant molecular axis requiring correction. Emerging diagnostic tools, such as skin methylation arrays, non-invasive microbiome swabs, and AI-assisted dermatoscopic analytics, facilitate longitudinal monitoring and early-stage therapeutic adjustments. Integration into wearable devices or smart skin patches could soon enable real-time feedback-guided intervention [74].

7.5. Regulatory and Ethical Considerations

The rapid convergence of cellular, microbial, and epigenetic therapies challenges conventional regulatory frameworks. For example, products combining live microbes with gene expression modulators may straddle classifications as biologics, drugs, or combination devices. Harmonization of international standards regarding potency, sterility, and long-term stability will be crucial. Ethically, the personalization of anti-aging therapies based on genomic or epigenomic profiling raises concerns about data privacy, access equity, and aesthetic normalization. Transparent data governance, rigorous clinical endpoints, and inclusion of diverse populations in clinical trials are necessary to ensure responsible translation [75].

8. Future Directions and Research Gaps

The integration of cellular senescence, epigenetic remodeling, and microbial ecology in skin aging has opened transformative avenues for both mechanistic understanding and therapeutic development. However, this conceptual convergence also highlights critical knowledge deficits and technological limitations that must be addressed to realize its translational potential.

8.1. Comprehensive Multi-Omics Integration

While single-axis analyses (e.g., transcriptomics, methylomics, or metagenomics) have yielded valuable insights, true systems-level understanding of skin aging demands concurrent multi-omics profiling—ideally at single-cell and spatial resolution. Integrating epigenetic landscapes with the spatial distribution of senescent cells and microbial communities will enable high-fidelity mapping of pathogenic micro-niches and molecular interdependencies [76,77]. Next-generation spatial multi-omics platforms—such as MERFISH, Slide-seq, and spatial ATAC-seq—remain underutilized in dermatological research but hold the potential to define microenvironmental crosstalk with unprecedented resolution. These tools can unravel how epigenetic states modulate microbial receptivity or how SASP gradients influence chromatin accessibility in neighboring progenitor pools [78].

8.2. Longitudinal Cohort Studies and Predictive Clocks

Most current studies rely on cross-sectional designs, limiting the ability to capture dynamic shifts in the skin aging trajectory. Prospective, longitudinal cohorts—integrating time-resolved epigenetic, microbiome, and senescence biomarkers—are essential to distinguish causality from correlation and identify early molecular tipping points.Development of skin-specific biological age clocks, calibrated by machine learning and validated against clinical phenotypes (e.g., wrinkling, TEWL, pigmentation irregularities), could provide actionable metrics for intervention timing, therapeutic efficacy, and population stratification. Integration with wearable sensors and high-frequency sampling could further accelerate temporal mapping [79].

8.3. Mechanistic Unpacking of Triadic Interactions

Although the interdependence of senescence, epigenetics, and microbiota is increasingly recognized, the molecular intermediates and regulatory nodes remain poorly defined. For instance, what microbial metabolites directly modulate HDAC activity in keratinocytes? Can SASP-induced chromatin remodeling alter the antimicrobial transcriptional landscape? These are mechanistic black boxes ripe for functional validation. CRISPR-based epigenome editing, loss-of-function microbial mutant libraries, and inducible senescence models in organotypic skin cultures can be instrumental in mapping these pathways. Dissecting bidirectional signaling—especially non-coding RNA–based communication—could uncover novel leverage points for multitargeted therapies [80].

8.4. Development of Precision and Synergistic Therapies

Future therapeutic design must prioritize modularity and personalizability. Polypharmacology platforms capable of targeting senescent cells while concurrently reprogramming epigenetic networks and modulating

microbial composition will likely yield superior regenerative outcomes. Exploration of microbiome-engineered drug delivery systems—wherein probiotic strains serve as both therapeutic producers and delivery vectors—could offer spatiotemporal precision unattainable by conventional formulations. Similarly, programmable RNA therapeutics and epigenetic nanodevices need to be adapted for topical use with tunable half-lives and minimal off-target effects [81].

8.5. Inclusivity in Dermatological Aging Research

Current datasets often lack representation across diverse phototypes, ethnic backgrounds, and geographic regions. Given that microbiome composition, immune tone, and epigenetic architecture are influenced by ancestry and environmental exposures, expanding inclusivity is essential for developing universally applicable anti-aging interventions. Global consortia and decentralized clinical trials should prioritize underrepresented populations, ensuring that both diagnostic tools and therapeutic strategies reflect the full spectrum of human skin biology [82,83].

CONCLUSION

Skin aging is an emergent phenotype governed by the dynamic interplay of cellular senescence, epigenetic dysregulation, and microbial ecosystem remodeling. Far from functioning in isolation, these domains converge through a network of reciprocal signaling pathways, transcriptional reprogramming, and metabolic feedback that collectively destabilize cutaneous homeostasis. Senescent cells exacerbate inflammation and chromatin instability; epigenetic drift reconfigures regenerative gene networks and microbial receptivity; and age-associated dysbiosis accelerates immunosenescence and barrier dysfunction. This triadic convergence underscores the inadequacy of monotherapeutic approaches and necessitates a systems-level framework for intervention. Advances in senolytics, epigenetic modulators, and microbiome engineering—when guided by patient-specific molecular profiling—offer a promising paradigm for precision dermatology. However, clinical translation remains contingent upon overcoming critical delivery barriers, ensuring regulatory harmonization, and addressing inter-individual variability through integrative omics and longitudinal modeling. By dissecting the molecular crosstalk among these pillars, this review provides a foundational blueprint for reimagining anti-aging therapeutics—not as isolated molecular silos, but as an interdependent biological continuum amenable to synchronized modulation. A future in which skin aging is not merely delayed but molecularly recalibrated is no longer conceptual it is increasingly actionable.

REFERENCES

1. Bellei B, Picardo M. Premature cell senescence in human skin: dual face in chronic acquired pigmentary disorders. Ageing Res Rev. (2020) 57:100981. doi: 10.1016/j.arr.2019.100981
2. Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. (2018) 31:461–5. doi: 10.1111/pcmr.12684
3. Kim NH, Choi SH, Lee TR, Lee CH, Lee AY. Cadherin 11 involved in basement membrane damage and dermal changes in melasma. Sweden: Medical Journals Sweden AB (2016). doi: 10.2340/00015555-2315
4. Gunin AG, Kornilova NK, Petrov VV, Vasil'eva OV. Age-related changes in the number and proliferation of fibroblasts in the human skin. Adv Gerontology = UspekhiGerontologii. (2011) 24:43–7.
5. Kang HY, Suzuki I, Lee DJ, Ha J, Reiniche P, Aubert J, et al. Transcriptional profiling shows altered expression of wnt pathway- and lipid metabolism-related genes as well as melanogenesis-related genes in melasma. J Invest Dermatol. (2011) 131:1692–700.
6. Espósito ACC, Brianezi G, de Souza NP, Miot LDB, Marques MEA, Miot HA. Exploring pathways for sustained melanogenesis in facial melasma: an immunofluorescence study. Int J Cosmetic Sci. (2018) 40:420–4.
7. Lopez-Pajares V, Yan K, Zarnegar BJ, Jameson KL, Khavari PA. Genetic pathways in disorders of epidermal differentiation. Trends genetics: TIG. (2013) 29:31–40.
8. Lu SY, Chang KW, Liu CJ, Tseng YH, Lu HH, Lee SY, et al. Ripe areca nut extract induces G1 phase arrests and senescence-associated phenotypes in normal human oral keratinocytes. Carcinogenesis. 2006;27(6):1276–84. doi:10.1093/carcin/bgi357
9. Cardinali G, Kovacs D, Picardo M. Mechanisms underlying post-inflammatory hyperpigmentation: lessons from solar lentigo. Ann Dermatol Venereol. 2012;139 Suppl4:S148–52. doi:10.1016/S0151-9638(12)70127-8
10. Rodríguez-Arámbula A, Torres-Álvarez B, Cortés-García D, Fuentes-Ahumada C, Castanedo-Cázares JP. CD4, IL-17, and COX-2 are associated with subclinical inflammation in malar melasma. Am J Dermatopathol. 2015;37(10):761–6. doi:10.1097/DAD.0000000000000378
11. Espósito ACC, Brianezi G, de Souza NP, Santos DC, Miot LDB, Miot HA. Ultrastructural characterization of damage in the basement membrane of facial melasma. Arch Dermatol Res. 2020;312(4):223–7. doi:10.1007/s00403-019-01979-w
12. Brianezi G, Handel AC, Schmitt JV, Miot LDB, Miot HA. Changes in nuclear morphology and chromatin texture of basal keratinocytes in melasma. J EurAcad Dermatol Venereol. 2015;29(4):809–12. doi:10.1111/jdv.2015.29.issue-4

13. Inomata S, Matsunaga Y, Amano S, Takada K, Kobayashi K, Tsunenaga M, et al. Possible involvement of gelatinases in basement membrane damage and wrinkle formation in chronically ultraviolet B-exposed hairless mouse. J Invest Dermatol. 2003;120(1):128–34. doi:10.1046/j.1523-1747.2003.12021.x
14. Rodier F, Campisi J. Four faces of cellular senescence. J Cell Biol. 2011;192(4):547–56. doi:10.1083/jcb.201009094
15. Coppé JP, Patil CK, Rodier F, Sun Y, Muñoz DP, Goldstein J, et al. Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic ras and the P53 tumor suppressor. PLoS Biol. 2008;6(12):2853–68. doi:10.1371/journal.pbio.0060301
16. Leary N, Walser S, He Y, Cousin N, Pereira P, Gallo A, et al. Melanoma-derived extracellular vesicles mediate lymphatic remodelling and impair tumour immunity in draining lymph nodes. J Extracell Vesicles. 2022;11:e12197. doi:10.1002/jev2.12197
17. Teng Y, Yu Y, Li S, Huang Y, Xu D, Tao X, et al. Ultraviolet radiation and basal cell carcinoma: an environmental perspective. Front Public Health. 2021;9:666528. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8339433/
18. Pittayapruek P, Meephansan J, Prapapan O, Komine M, Ohtsuki M. Role of matrix metalloproteinases in photoaging and photocarcinogenesis. Int J Mol Sci. 2016;17(6):868. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4926402/
19. Poswar FO, Fraga CAC, Farias LC, Feltenberger JD, Cruz VPD, Santos SHS, et al. Immunohistochemical analysis of TIMP-3 and MMP-9 in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma. Pathol Res Pract. 2013;209(11):705–9. doi:10.1016/j.prp.2013.08.002
20. Ciurea ME, Cernea D, Georgescu CC, Cotoi OS, Pătraşcu V, Pârvănescu H, et al. Expression of CXCR4, MMP-13 and β-catenin in different histological subtypes of facial basal cell carcinoma. Rom J Morphol Embryol. 2013;54(4):939–51.
21. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the U.S. population, 2012. JAMA Dermatol. 2015;151(10):1081–6. doi:10.1001/jamadermatol.2015.1187
22. Gibson GE, Ahmed I. Perianal and genital basal cell carcinoma: a clinicopathologic review of 51 cases. J Am Acad Dermatol. 2001;45(1):68–71. doi:10.1067/mjd.2001.114588
23. You L, Han Z, Chen H, Chen L, Lin Y, Wang B, et al. The role of N6-methyladenosine (m6A) in kidney diseases. Front Med. 2023;10:1247690. doi:10.3389/fmed.2023.1247690
24. Rosenstein BS, Phelps RG, Weinstock MA, Bernstein JL, Gordon ML, Rudikoff D, et al. P53 mutations in basal cell carcinomas arising in routine users of sunscreens. PhotochemPhotobiol. 1999;70(6):798–806. doi:10.1111/j.751-097.1999.tb08285.x
25. Scott GA, Laughlin TS, Rothberg PG. Mutations of the TERT promoter are common in basal cell carcinoma and squamous cell carcinoma. Mod Pathol. 2014;27(4):516–23. Available from: https://www.sciencedirect.com/science/article/pii/S0893395222018439
26. Pópulo H, Boaventura P, Vinagre J, Batista R, Mendes A, Caldas R, et al. TERT promoter mutations in skin cancer: the effects of sun exposure and X-irradiation. J Invest Dermatol. 2014;134(9):2251–7. Available from:https://www.sciencedirect.com/science/article/pii/S0022202X15369281
27. Oh ST, Kim HS, Yoo NJ, Lee WS, Cho BK, Reichrath J. Increased immunoreactivity of membrane type-1 matrix metalloproteinase (MT1-MMP) and β-catenin in high-risk basal cell carcinoma. Br J Dermatol. 2011;165(6):1197–204. doi:10.1111/j.1365-2133.2011.10506.x
28. Chu CY, Cha ST, Chang CC, Hsiao CH, Tan CT, Lu YC, et al. Involvement of matrix metalloproteinase-13 in stromal-cell-derived factor 1 alpha-directed invasion of human basal cell carcinoma cells. Oncogene. 2007;26(17):2491–501. doi:10.1038/sj.onc.1210040
29. Boyd S, Tolvanen K, Virolainen S, Kuivanen T, Kyllönen L, Saarialho-Kere U. Differential expression of stromal MMP-1, MMP-9 and TIMP-1 in basal cell carcinomas of immunosuppressed patients and controls. Virchows Arch. 2008;452(1):83–90. doi:10.1007/s00428-007-0526-0
30. Bargou RC, Emmerich F, Krappmann D, Bommert K, Mapara MY, Arnold W, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100(12):2961–9. doi:10.1172/JCI119849
31. NfκB-dependent down-regulation of tumor necrosis factor receptor-associated proteins contributes to interleukin-1-mediated enhancement of ultraviolet B-induced apoptosis. J Biol Chem. 2005. Available from: https://www.sciencedirect.com/science/article/pii/S0021925820692341
32. Weng H, Deng Y, Xie Y, Liu H, Gong F. Expression and significance of HMGB1, TLR4 and NF-κB p65 in human epidermal tumors. BMC Cancer. 2013;13:311. doi:10.1186/1471-2407-13-311
33. Johnson KE, Wulff BC, Oberyszyn TM, Wilgus TA. Ultraviolet light exposure stimulates HMGB1

release by keratinocytes. Arch Dermatol Res. 2013;305(9):805–15. doi:10.1007/s00403-013-1401-2

34. Nguyen AH, Detty SQ, Agrawal DK. Clinical implications of high-mobility group box-1 (HMGB1) and the receptor for advanced glycation end-products (RAGE) in cutaneous malignancy: A systematic review. Anticancer Res. 2017;37(1):1–7. Available from: https://ar.iiarjournals.org/content/37/1/1
35. Russo I, Cona C, Saponeri A, Bassetto F, Baldo V, Alaibac M. Association between toll-like receptor 7 Gln11Leu single-nucleotide polymorphism and basal cell carcinoma. Biomed Rep. 2016;4(5):573–6. doi:10.3892/br.2016.597
36. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J, et al. Intragenic ERBB2 kinase mutations in tumours. Nature. 2004;431(7008):525–6. doi:10.1038/431525b
37. Rao VH, Vogel K, Yanagida JK, Marwaha N, Kandel A, Trempus C, et al. ERBB2 up-regulation of ADAM12 expression accelerates skin cancer progression. Mol Carcinog. 2015;54(10):1411–22. doi:10.1002/mc.22171
38. Briso EM, Guinea-Viniegra J, Bakiri L, Rogon Z, Petzelbauer P, Eils R, et al. Inflammation-mediated skin tumorigenesis induced by epidermal c-Fos. Genes Dev. 2013;27(18):1959–73. doi:10.1101/gad.223339.113
39. De Simoni E, Candelora M, Belleggia S, Rizzetto G, Molinelli E, Capodaglio I, et al. Role of antioxidants supplementation in the treatment of atopic dermatitis: A critical narrative review. Front Nutr. 2024; 11:1393673.
40. Ventura A, Pellegrini C, Cardelli L, Rocco T, Ciciarelli V, Peris K, et al. Telomeres and telomerase in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(6):1333.
41. Bottomley MJ, Thomson J, Harwood C, Leigh I. The role of the immune system in cutaneous squamous cell carcinoma. Int J Mol Sci. 2019;20(8):2009.
42. Martins VL, Vyas JJ, Chen M, Purdie K, Mein CA, South AP, et al. Increased invasive behaviour in cutaneous squamous cell carcinoma with loss of basement-membrane type VII collagen. J Cell Sci. 2009;122(Pt 11):1788–99. doi:10.1242/jcs.042895
43. Ahmed Haji Omar A, Haglund C, Virolainen S, Häyry V, Atula T, Kontio R, et al. MMP-7, MMP-8, and MMP-9 in oral and cutaneous squamous cell carcinomas. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;119(4):459–67. doi: 10.1016/j.oooo.2014.12.019
44. Lederle W, Hartenstein B, Meides A, Kunzelmann H, Werb Z, Angel P, et al. MMP13 as a stromal mediator in controlling persistent angiogenesis in skin carcinoma. Carcinogenesis. 2010;31(7):1175–84. doi:10.1093/carcin/bgp248
45. Xia YH, Li M, Fu DD, Xu SL, Li ZG, Liu D, et al. Effects of PTTG down-regulation on proliferation and metastasis of the SCL-1 cutaneous squamous cell carcinoma cell line. Asian Pac J Cancer Prev. 2013;14(11):6245–8. doi:10.7314/APJCP.2013.14.11.6245
46. Kuivanen T, Jeskanen L, Kyllönen L, Isaka K, Saarialho-Kere U. Matrix metalloproteinase-26 is present more frequently in squamous cell carcinomas of immunosuppressed compared with immunocompetent patients. J Cutan Pathol. 2009;36(9):929–36. doi:10.1111/j.1600-0560.2009.01188.x
47. Rivera C, Venegas B. Histological and molecular aspects of oral squamous cell carcinoma: A review. Oncol Lett. 2014;8(1):7–11. doi:10.3892/ol.2014.2103
48. Jung DW, Che ZM, Kim J, Kim K, Kim KY, Williams D, et al. Tumor-stromal crosstalk in invasion of oral squamous cell carcinoma: A pivotal role of CCL7. Int J Cancer. 2010;127(2):332–44. doi:10.1002/ijc.25062
49. de Oliveira Poswar F, de Carvalho Fraga CA, Gomes ESB, Farias LC, Souza LWF, Santos SHS, et al. Protein expression of MMP-2 and MT1-MMP in actinic keratosis, squamous cell carcinoma of the skin, and basal cell carcinoma. Int J SurgPathol. 2015;23(1):20–5. doi:10.1177/1066896914540998
50. Toll A, Salgado R, Yébenes M, Martín-Ezquerra G, Gilaberte M, Baró T, et al. MYC gene numerical aberrations in actinic keratosis and cutaneous squamous cell carcinoma. Br J Dermatol. 2009;161(5):1112–8. doi:10.1111/j.1365-2133.2009.09351.x
51. Pellegrini C, Maturo MG, Martorelli C, Suppa M, Antonini A, Kostaki D, et al. Characterization of melanoma susceptibility genes in high-risk patients from central Italy. Melanoma Res. 2017;27(3):258–67. doi:10.1097/CMR.0000000000000323
52. Bertrand JU, Steingrimsson E, Jouenne F, Bressac-De Paillerets B, Larue L. Melanoma risk and melanocyte biology. Acta Derm Venereol. 2020;100(8):adv00140. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9189750/
53. Brash DE. UV signature mutations. PhotochemPhotobiol. 2015;91(1):15–26. doi:10.1111/php.12464
54. Gaffal E, Landsberg J, Bald T, Sporleder A, Kohlmeyer J, Tüting T. Neonatal UVB exposure accelerates melanoma growth and enhances distant metastases in HGF-CDK4(R24C) C57BL/6 mice. Int J Cancer. 2011;129(2):285–94. doi:10.1002/ijc.25971
55. Cheung M, Kadariya Y, Talarchek J, Pei J, Ohar JA, Kayaleh OR, et al. Germline BAP1 mutation in a family with high incidence of multiple primary cancers and a potential gene-environment interaction. Cancer Lett. 2015;369(2):261–5. doi:10.1016/j.canlet.2015.09.011
56. Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, et al. MC1R is a potent regulator of

PTEN after UV exposure in melanocytes. Mol Cell. 2013;51(4):409–22. doi:10.1016/j.molcel.2013.08.010

57. Kawaguchi M, Valencia JC, Namiki T, Suzuki T, Hearing VJ. Diacylglycerol kinase regulates tyrosinase expression and function in human melanocytes. J Invest Dermatol. 2012;132(11):2791–9. doi:10.1038/jid.2012.261
58. Friedmann PS, Wren FE, Matthews JN. Ultraviolet stimulated melanogenesis by human melanocytes is augmented by diacylglycerol but not TPA. J Cell Physiol. 1990;142(2):334–41. doi:10.1002/jcp.1041420216
59. Eller MS, Ostrom K, Gilchrest BA. DNA damage enhances melanogenesis. Proc Natl Acad Sci U S A. 1996;93(3):1087–92. doi:10.1073/pnas.93.3.1087
60. Khlgatian MK, Hadshiew IM, Asawanonda P, Yaar M, Eller MS, Fujita M, et al. Tyrosinase gene expression is regulated by P53. J Invest Dermatol. 2002;118(1):126–32. doi:10.1046/j.0022-202x.2001.01667.x
61. Cui R, Widlund HR, Feige E, Lin JY, Wilensky DL, Igras VE, et al. Central role of P53 in the suntan response and pathologic hyperpigmentation. Cell. 2007;128(5):853–64. doi:10.1016/j.cell.2006.12.045
62. Goding CR, Arnheiter H. MITF-the first 25 years. Genes Dev. 2019;33(15–16):983–1007. doi:10.1101/gad.324657.119
63. Leight JL, Tokuda EY, Jones CE, Lin AJ, Anseth KS. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition. Proc Natl Acad Sci U S A. 2015;112(17):5366–71. doi:10.1073/pnas.1505662112
64. Britto SM, Shanthakumari D, Agilan B, Radhiga T, Kanimozhi G, Prasad NR. Apigenin prevents ultraviolet-B radiation induced cyclobutane pyrimidine dimers formation in human dermal fibroblasts. Mutat Res Genet Toxicol Environ Mutagen. 2017; 821:28–35.
65. Das S, Das J, Paul A, Samadder A, Khuda-Bukhsh AR. Apigenin, a bioactive flavonoid from Lycopodium clavatum, stimulates nucleotide excision repair genes to protect skin keratinocytes from ultraviolet B-induced reactive oxygen species and DNA damage. J Acupunct Meridian Stud. 2013; 6:252–62.
66. Wang SC, Chen SF, Lee YM, Chuang CL, Bau DT, Lin SS. Baicalin scavenges reactive oxygen species and protects human keratinocytes against UVC-induced cytotoxicity. In Vivo. 2013; 27:707.
67. Hahn HJ, Kim KB, Bae S, Choi BG, An S, Ahn KJ, et al. Pretreatment of ferulic acid protects human dermal fibroblasts against ultraviolet A irradiation. Ann Dermatol. 2016; 28:740–8.
68. Seo SH, Jeong GS. Fisetin inhibits TNF-α-induced inflammatory action and hydrogen peroxide-induced oxidative damage in human keratinocyte HaCaT cells through PI3K/Akt/Nrf-2-mediated heme oxygenase-1 expression. Int J Mol Sci.2022;23: -6
69. Chiang HM, Chan SY, Chu Y, Wen KC. Fisetin ameliorated photodamage by suppressing the mitogen-activated protein kinase/matrix metalloproteinase pathway and nuclear factor-κB pathways. J Agric Food Chem. 2015;63(20):4551–60.
70. Hwang E, Park SY, Lee HJ, Lee TY, Sun ZW, Yi TH. Gallic acid regulates skin photoaging in UVB-exposed fibroblast and hairless mice. Phytother Res. 2014;28(12):1778–88.
71. Reeve VE, Widyarini S, Domanski D, Chew E, Barnes K. Protection against photoaging in the hairless mouse by the isoflavone equol. PhotochemPhotobiol. 2005;81(6):1548–53.
72. Ansari MJ, Alshetaili A, Aldayel IA, Alablan FM, Alsulays B, Alshahrani S, et al. Formulation, characterization, in vitro and in vivo evaluations of self-nanoemulsifying drug delivery system of luteolin. J Taibah Univ Sci. 2020;14(1):1386–401.
73. Martinez RM, Pinho-Ribeiro FA, Steffen VS, Caviglione CV, Vignoli JA, Barbosa DS, et al. Naringenin inhibits UVB irradiation-induced inflammation and oxidative stress in the skin of hairless mice. J Nat Prod. 2015;78(7):1647–55.
74. Martinez RM, Pinho-Ribeiro FA, Steffen VS, Silva TC, Caviglione CV, Bottura C, et al. Topical formulation containing naringenin: Efficacy against ultraviolet B irradiation-induced skin inflammation and oxidative stress in mice. PLoS One. 2016;11(1): e0146296.
75. Jang HJ, Yang KE, Oh WK, Lee SI, Hwang IH, Ban KT, et al. Nectandrin B-mediated activation of the AMPK pathway prevents cellular senescence in human diploid fibroblasts by reducing intracellular ROS levels. Aging (Albany NY). 2019;11(10):3731–49.
76. Maruki-Uchida H, Kurita I, Sugiyama K, Sai M, Maeda K, Ito T. The protective effects of piceatannol from passion fruit (Passiflora edulis) seeds in UVB-irradiated keratinocytes. Biol Pharm Bull. 2013;36(6):845–9.
77. Sohn EJ, Kim JM, Kang SH, Kwon J, An HJ, Sung JS, et al. Restoring effects of natural anti-oxidant quercetin on cellular senescent human dermal fibroblasts. Am J Chin Med. 2018;46(4):853–73.
78. Sánchez-Marzo N, Pérez-Sánchez A, Barrajón-Catalán E, Castillo J, Herranz-López M, Micol V. Rosemary diterpenes and flavanone aglycones provide improved genoprotection against UV-induced DNA damage in a human skin cell model. Antioxidants. 2020;9(3):255.
79. Pérez-Sánchez A, Barrajón-Catalán E, Herranz-López M, Castillo J, Micol V. Lemon balm extract (Melissa officinalis L.) promotes melanogenesis and prevents UVB-induced oxidative stress and DNA damage in a skin cell model. J Dermatol Sci. 2016;84(2):169–77.

80. Agulló-Chazarra L, Borrás-Linares I, Lozano-Sánchez J, Segura-Carretero A, Micol V, Herranz-López M, et al. Sweet cherry byproducts processed by green extraction techniques as a source of bioactive compounds with antiaging properties. Antioxidants. 2020; 9(5):418.
81. Olivieri A, Manzione L. Dasatinib: A new step in molecular target therapy. Ann Oncol. 2007;18(Suppl 6):vi42–6.
82. Hickson LJ, Langhi Prata LGP, Bobart SA, Evans TK, Giorgadze N, Hashmi SK, et al. Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of dasatinib plus quercetin in individuals with diabetic kidney disease. EBioMedicine. 2019; 47:446–56.
83. Justice JN, Nambiar AM, Tchkonia T, LeBrasseur NK, Pascual R, Hashmi SK, et al. Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. 2019; 40:554–63.